The gene encoding phosphodiesterase 4D confers risk of ischemic stroke

Nature Genetics

Volumn 35, Issue 2, 2003, Pages 131-138

  Gretarsdottir, Solveig ^a   Thorleifsson, Gudmar ^a   Reynisdottir, Sigridur Th ^a   Manolescu, Andrei ^a   Jonsdottir, Sif ^a   Jonsdottir, Thorbjörg ^a   Gudmundsdottir, Thorunn ^a   Bjarnadottir, Sigrun M ^a   Einarsson, Olafur B ^a   Gudjonsdottir, Herdis M ^a   Hawkins, Malcolm ^a   Gudmundsson, Gudmundur ^a   Gudmundsdottir, Hrefna ^a   Andrason, Hjalti ^a   Gudmundsdottir, Asta S ^a   Sigurdardottir, Matthildur ^a   Chou, Thomas T ^a   Nahmias, Joseph ^a   Goss, Shyamali ^a   Sveinbjörnsdottir, Sigurlaug ^b   Valdimarsson, Einar M ^b   Jakobsson, Finnbogi ^b   Agnarsson, Uggi ^b   Gudnason, Vilmundur ^c   Thorgeirsson, Gudmundur ^c   Fingerle, Jurgen ^d   Gurney, Mark ^a   Gudbjartsson, Daniel ^a   Frigge, Michael L ^a   Kong, Augustine ^a   Stefansson, Kari ^a   Gulcher, Jeffrey R ^a   more..

^a DECODE GENETICS   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c Heart Preventive Clinic Reykjavik   (Iceland)

^d Preclinical Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; MESSENGER RNA; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHROMOSOME 5Q; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME REGULATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; ICELAND; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 5' UNTRANSLATED REGIONS; BASE SEQUENCE; BRAIN ISCHEMIA; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 5; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOENZYMES; LINKAGE DISEQUILIBRIUM; MICROSATELLITE REPEATS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0141819194     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1245     Document Type: Article

References (42)

1. Sacco, R.L. et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 28, 1507-1517 (1997).
2. Bonita, R. Epidemiology of stroke. Lancet 339, 342-344 (1992).
3. Caplan, L.R. Caplan's Stroke: A Clinical Approach. (Butterworth-Heinemann, Boston, 2000).
4. Adams, H.P.Jr. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24, 35-41 (1993).
5. Fisher, C.M. Lacunar strokes and infarcts: a review. Neurology 32, 871-876 (1982).
6. Alberts, M.J. Genetics of Cerebrovascular Disease (Futura, New York, 1999).
7. Hassan, A. & Markus, H.S. Genetics and ischaemic stroke. Brain 123, 1784-1812 (2000).
8. Leys, D. et al. Stroke prevention: management of modifiable vascular risk factors. J. Neurol. 249, 507-517 (2002).
9. Brass, L.M. & Alberts, M.J. The genetics of cerebrovascular disease. Baillieres Clin. Neurol. 4, 221-245 (1995).
10. Tournier-Lasserve, E. et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat. Genet. 3, 256-259 (1993).
11. Joutel, A. et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383, 707-710 (1996).
12. Palsdottir, A. et al. Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet 2, 603-604 (1988).
13. Levy, E. et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124-1126 (1990).
14. Gunel, M., Awad, I.A., Anson, J. & Lifton, R.P. Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21. Proc. Natl. Acad. Sci. USA 92, 6620-6624 (1995).
15. Laberge-le Couteulx, S. et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat. Genet. 23, 189-193 (1999).
16. Sahoo, T. et al. Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum. Mol. Genet. 8, 2325-2333 (1999).
17. Gretarsdottir, S. et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am. J. Hum. Genet. 70, 593-603 (2002).
18. Terwilliger, J.D. & Ott, J. A haplotype-based 'haplotype relative risk' approach to detecting allelic associations. Hum. Hered. 42, 337-346 (1992).
19. Falk, C.T. & Rubinstein, P. Haplotype relative risks: an easy reliable way to construct a proper control sample for risk calculations. Ann. Hum. Genet. 51 (Pt 3), 227-233 (1987).
20. Houslay, M.D. & Adams, D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370, 1-18 (2003).
21. Liu, H. & Maurice, D.H. Phosphorylation-mediated activation and translocation of the cyclic AMP- specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J. Biol. Chem. 274, 10557-10565 (1999).
22. Liu, H. et al. Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J. Biol. Chem. 275, 26615-26624 (2000).
23. Baillie, G., MacKenzie, S.J. & Houslay, M.D. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol. Pharmacol. 60, 1100-1111 (2001).
24. Jin, S.L. & Conti, M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl. Acad. Sci. USA 99, 7628-7633 (2002).
25. Landells, L.J. et al. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br. J. Pharmacol. 133, 722-729 (2001).
26. Fukumoto, S. et al. Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ. Res. 85, 985-991 (1999).
27. Ogawa, S. et al. Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels. Am. J. Physiol. 262, C546-C554 (1992).
28. Stelzner, T.J., Weil, J.V. & O'Brien, R.F. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J. Cell Physiol. 139, 157-166 (1989).
29. Pan, X., Arauz, E., Krzanowski, J.J., Fitzpatrick, D.F. & Polson, J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48, 827-835 (1994).
30. Palmer, D., Tsoi, K. & Maurice, D.H. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ. Res. 82, 852-861 (1998).
31. Indolfi, C. et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat. Med. 3, 775-779 (1997).
32. Indolfi, C. et al. 8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. J. Am. Coll. Cardiol. 36, 288-293 (2000).
33. Tilley, S.L., Coffman, T.M. & Koller, B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108, 15-23 (2001).
34. Vicini, E. & Conti, M. Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol. Endocrinol. 11, 839-850 (1997).
35. Le Jeune, I.R., Shepherd, M., Van Heeke, G., Houslay, M.D. & Hall, I.P. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J. Biol. Chem. 277, 35980-35989 (2002).
36. Gulcher, J.R., Kristiansson, K., Gudbjartsson, H. & Stefansson, K. Protection of privacy by third-party encryption in genetic research in Iceland. Eur. J. Hum. Genet. 8, 739-742 (2000).
37. Chen, X., Zehnbauer, B., Gnirke, A. & Kwok, P.Y. Fluorescence energy transfer detection as a homogeneous DNA diagnostic method. Proc. Natl. Acad. Sci. USA 94, 10756-10761 (1997).
38. Risch, N. & Teng, J. The relative power of family-based and case-control designs for linkage disequilibrium studies of complex human diseases I. DNA pooling. Genome Res. 8, 1273-1288 (1998).
39. Rice, J.A. Generalized likelihood ratio tests. in Mathematical Statistics and Data Analysis 308-310 (International Thomson Publishing, Belmont, California, 1995).
40. Dempster, A.P., Laird, N.M. & Rubin, D.B. Maximum likelihood estimation from incomplete data via the EM algorithm (with discussion). J. R. Stat. Soc. Ser. B Stat. Med. 39, 1-38 (1971).
41. Lewontin, R. The interaction of selection and linkage I. General considerations: Heterotic models. Genetics 49, 49-67 (1964).
42. Hill, W.G. & Robertson, A. Linkage disequilibrium in finite populations. Theor. Appl. Genet. 22, 226-231 (1968).